Melinda Reyes1, Mark Georgy2, Lorenzo Brook3, Orlando Ortiz4, Allan Brook5, Vikas Agarwal6, Mario Muto7, Luigi Manfre8, Stefano Marcia9, Bassem A Georgy10. 1. Point Loma Nazarene University, San Diego, California, USA. 2. Department of Family practice and Public Health, University of California, San Diego, La Jolla, California, USA. 3. Department of Psychology, Boston University, Boston University, Boston, Massachusetts, USA. 4. Department of Radiology, Winthrop-University Hospital, Clinical Professor of Radiology at the State University of New York-Stony Brook, Mineola, New York, USA. 5. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. 6. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 7. Cardarelli Hosp Naples Italy, Naples, Italy. 8. Department of Neurosurgery -Minimal Invasive Spine, Institute of Oncology in Mediterranean (IOM), Viagrande, Catania, Italy. 9. Chief of Radiology Unit, SS Trinità Hospital-ASL Cagliari, Cagliari, Italy. 10. San Diego Imaging, University of California, San Diego, San Diego, California, USA.
Abstract
BACKGROUND: Treatment of spinal metastatic lesions by radiofrequency ablation (RFA) before cementation can potentially help in local tumor control and pain relief. This is often limited by access and tumor location. This study reports multicenter clinical and imaging outcomes following targeted RFA (t-RFA) and cement augmentation in neoplastic lesions of the spine. MATERIAL AND METHODS: A retrospective multicenter study of 49 patients with 72 painful vertebral lesions, evaluated for clinical and imaging outcomes following RFA and cement augmentation of spinal metastatic lesions, was undertaken. Visual Analogue Pain score (VAS) and Oswestry Disability Index (ODI) were obtained before and 2-4 weeks after treatment. Pre- and post-procedure imaging examinations including MRI and positron emission tomography (PET) were also evaluated. RESULTS: Mean ablation time was 3.7±2.5 min (range 0.92-15). Mean VAS scores decreased from 7.9±2.5 pre-procedure to 3.5±2.6 post-procedure (p<0.0001). Mean ODI scores improved from 34.9±18.3 to 21.6±13.8 post-procedure (p<0.0001). Post-contrast MRI resulted in a predictable pattern of decreased tumor volume and an enhancing rim. Metabolically active lesions in pre-procedure PET scans (n=10 levels) showed decreased fluorodeoxyglucose activity after ablation. CONCLUSIONS: t-RFA followed by vertebral augmentation in malignant vertebral lesions resulted in significant pain reduction and functional status improvement, with no major complications. t-RFA permitted access to vertebral lesions and real-time accurate monitoring of the ablation zone temperature. Post-procedure MRI and PET examinations correlated with a favorable tumor response and helped to monitor tumor growth and the timing of adjuvant therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: Treatment of spinal metastatic lesions by radiofrequency ablation (RFA) before cementation can potentially help in local tumor control and pain relief. This is often limited by access and tumor location. This study reports multicenter clinical and imaging outcomes following targeted RFA (t-RFA) and cement augmentation in neoplastic lesions of the spine. MATERIAL AND METHODS: A retrospective multicenter study of 49 patients with 72 painful vertebral lesions, evaluated for clinical and imaging outcomes following RFA and cement augmentation of spinal metastatic lesions, was undertaken. Visual Analogue Pain score (VAS) and Oswestry Disability Index (ODI) were obtained before and 2-4 weeks after treatment. Pre- and post-procedure imaging examinations including MRI and positron emission tomography (PET) were also evaluated. RESULTS: Mean ablation time was 3.7±2.5 min (range 0.92-15). Mean VAS scores decreased from 7.9±2.5 pre-procedure to 3.5±2.6 post-procedure (p<0.0001). Mean ODI scores improved from 34.9±18.3 to 21.6±13.8 post-procedure (p<0.0001). Post-contrast MRI resulted in a predictable pattern of decreased tumor volume and an enhancing rim. Metabolically active lesions in pre-procedure PET scans (n=10 levels) showed decreased fluorodeoxyglucose activity after ablation. CONCLUSIONS: t-RFA followed by vertebral augmentation in malignant vertebral lesions resulted in significant pain reduction and functional status improvement, with no major complications. t-RFA permitted access to vertebral lesions and real-time accurate monitoring of the ablation zone temperature. Post-procedure MRI and PET examinations correlated with a favorable tumor response and helped to monitor tumor growth and the timing of adjuvant therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Ning Mao Kam; Julian Maingard; Hong Kuan Kok; Dinesh Ranatunga; Duncan Brooks; William C Torreggiani; Peter L Munk; Michael J Lee; Ronil V Chandra; Hamed Asadi Journal: Curr Treat Options Oncol Date: 2017-11-16